Bionow | News

Monument Therapeutics Secures £1M Investment to Advance Schizophrenia Treatment...

Oct 21st 2024

Monument Therapeutics, a leader in precision neuroscience, has announced a significant £1 million equity investment from the Forster Foundation, a charitable organization.

Tech Pioneer Awarded to Manchester Entrepreneur

Jul 5th 2024

Dr. Farid Khan, CEO of PharmaKure was awarded Asian Tech Pioneer in his work in Biotech.

£2.1m award to develop eye cell ‘bandage’

Jun 28th 2024

A team of vision researchers from the University of Liverpool have received £2.1m to develop a contact lens that can repair eye damage.

PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the tre...

Jan 5th 2024

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease

PharmaKure submits MHRA CTA for Phase 2a Clinical Trial of PK051 in patients wit...

Oct 24th 2023

PharmaKure submits MHRA CTA for Phase 2a Clinical Trial of PK051 in patients with mild cognitive impairment Clinical Trial Application filed for combined drug targeting amyloid deposits as...

Northern Gritstone invests in Pencil Biosciences, developer of novel gene editin...

Oct 3rd 2023

Pencil Biosciences is developing a fully synthetic gene modulation and editing platform that will have impact across a wide range of applications, including new therapeutic options for patie...

Why is Diverse Leadership in STEM Important?

Oct 20th 2022

Jacob Midwinter – Director of Sales and Search by SRG, discusses the key success factors behind driving diversity in leadership, as well as the challenges and opportunities leaders in STEM...

Inside Peak April 2021

Apr 30th 2021

Read the latest issue of Peak Proteins' monthly newsletter - Inside Peak.

Accessing Emerging Technologies at Alderley Park

Apr 1st 2021

Dr Raquel Faba Rodríguez, Protein Purification Specialist at Peak Proteins with be joining Cytiva and Alderley Park at this online event.

New Chief Executive for Innovation Agency

Oct 26th 2020

The Innovation Agency has appointed Dr Phil Jennings as chief executive, four years after he joined the organisation as medical director, later becoming deputy chief executive.

Sygnature Discovery expands DMPK capabilities with acquisition of XenoGesis

Sep 24th 2020

Sygnature has significantly expanded our DMPK capabilities and expertise with the acquisition of XenoGesis, the UK’s largest independent laboratory-based CRO specialising in pre-clinical D...

Knowledge Transfer Partnership – Quay Pharma and LJMU

Sep 10th 2020

Quay Pharma (Deeside, UK) and Liverpool John Moores University (LJMU – Liverpool, UK) are delighted to announce that their Knowledge Transfer Partnership (KTP) funding application has been...

News